Related content

Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil.

By Negrier S.   Caty A.   Lesimple T.   J-Y D.   Escudier B.   J-F R.   Viens P.   Gomez F.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 84-84

Elsevier

Access to resources Recommend Favorite

Phase II trial of interleukin 2, interferon , and 5-fluorouracil in metastatic renal cell cancer - a cytokine working group study.

By Dutcher J.   Logan T.   Gordon M.   Sosman J.   Weiss G.   Margolin K.   Plasse T.   Mier J.   Lotze M.   Clark J.   Atkins M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-84

Elsevier

Access to resources Recommend Favorite

Phase II trial of cisplatin, 5-fluorouracil, and interferon- -2B as first line treatment of advanced urothelial cancer

By Bazarbashi S.   Pai C.   Raja M.A.   Rahal M.   Ezzat A.   Hanash K.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 3, 2003-05 ,pp. : 185-189

Elsevier

Access to resources Recommend Favorite

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer - a phase II study.

By Allen M.   Vaughan M.   Webb A.   Johnston S.   Savage P.   Eisen T.   Bates S.   Morre J.   Ahern R.   Gore M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 7, Iss. 2, 2002-03 ,pp. : 83-83

Elsevier

Access to resources Recommend Favorite

Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b

By Lyrdal David   Stierner Ulrika   Lundstam Sven  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 901-908

Informa Healthcare

Access to resources Recommend Favorite